{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "ACE-2",
      "COVID-19",
      "RAS",
      "SARS-CoV-2"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33835386",
  "DateCompleted": {
    "Year": "2021",
    "Month": "05",
    "Day": "05"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "04",
        "Day": "09"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1007/s12012-021-09649-y"
    ],
    "Journal": {
      "ISSN": "1559-0259",
      "JournalIssue": {
        "Volume": "21",
        "Issue": "6",
        "PubDate": {
          "Year": "2021",
          "Month": "Jun"
        }
      },
      "Title": "Cardiovascular toxicology",
      "ISOAbbreviation": "Cardiovasc Toxicol"
    },
    "ArticleTitle": "Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.",
    "Pagination": {
      "StartPage": "498",
      "EndPage": "503",
      "MedlinePgn": "498-503"
    },
    "Abstract": {
      "AbstractText": [
        "In March 2019 began the global pandemic COVID-19 caused by the new Coronavirus SARS-CoV-2. The first cases of SARS-CoV-2 infection occurred in November-19 in Wuhan, China. The preventive measures taken did not prevent the rapid spread of the virus to all countries around the world. To date, there are about 2.54 million deaths, effective vaccines are in clinical trials. SARS-CoV-2 uses the ACE-2 protein as an intracellular gateway. ACE-2 is a key component of the Renin Angiotensin (RAS) system, a key regulator of cardiovascular function. Considering the key role of ACE-2 in COVID-19 infection, both as an entry receptor and as a protective role, especially for the respiratory tract, and considering the variations of ACE-2 and ACE during the stages of viral infection, it is clear the important role that the pharmacological regulation of RAS and ACE-2 can assume. This biological knowledge suggests different pharmacological approaches to treat COVID-19 by modulating RAS, ACE-2 and the ACE/ACE2 balance that we describe in this article."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0001-9298-6783"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pharmaceutical Department, Usl Umbria 1, A.Migliorati street, 06132, Perugia, Italy. francesco.ferrara@uslumbria1.it."
          }
        ],
        "LastName": "Ferrara",
        "ForeName": "F",
        "Initials": "F"
      },
      {
        "Identifier": [
          "0000-0003-2623-166X"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pharmaceutical Department, Usl Umbria 1, A.Migliorati street, 06132, Perugia, Italy."
          }
        ],
        "LastName": "Vitiello",
        "ForeName": "A",
        "Initials": "A"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cardiovasc Toxicol",
    "NlmUniqueID": "101135818",
    "ISSNLinking": "1530-7905"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Angiotensin Receptor Antagonists"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Angiotensin-Converting Enzyme Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Receptors, Virus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Recombinant Proteins"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "ACE2 protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "Angiotensin-Converting Enzyme 2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Angiotensin Receptor Antagonists"
    },
    {
      "QualifierName": [
        "metabolism",
        "therapeutic use"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme 2"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme Inhibitors"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "enzymology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Host-Pathogen Interactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects",
        "enzymology",
        "virology"
      ],
      "DescriptorName": "Lung"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Receptors, Virus"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Recombinant Proteins"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Renin-Angiotensin System"
    },
    {
      "QualifierName": [
        "drug effects",
        "metabolism",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Internalization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "All Authors declare that they have no conflict of interest to disclose."
}